Evidence map›Paper›PMID 30675626›Full record

ReviewDiabetologia2019

Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes.

Jessica L Dunne, Sarah J Richardson, Mark A Atkinson, Maria E Craig, Knut Dahl-Jørgensen, Malin Flodström-Tullberg, Heikki Hyöty, Richard A Insel, Åke Lernmark, Richard E Lloyd and 2 more

Open access · hybridAbstract readReview
In one paragraph

Review in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Prevention of Type 1 Diabetes in Children: A Worthy Challenge?International journal of environmental research and public health · 2023
    Review
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 6 countries.

Jessica L DunneJDRF, 26 Broadway, 14th Floor, New York, NY, 10004, USA. JDunne@JDRF.org.
Sarah J RichardsonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Building, Barrack Road, Exeter, EX2 5DW, UK. S.Richardson@exeter.ac.uk.
Mark A AtkinsonDepartments of Pathology and Pediatrics, University of Florida, College of Medicine, Gainesville, FL, USA.
Maria E CraigSchool of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Knut Dahl-JørgensenDepartment of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Malin Flodström-TullbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Heikki HyötyFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Richard A InselInsel Consulting, LLC, Rochester, NY, USA.
Åke LernmarkDepartment of Clinical Sciences, Lund University/CRC, Skåne University Hospital, Malmö, Sweden.
Richard E LloydDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Noel G MorganInstitute of Biomedical and Clinical Science, University of Exeter Medical School, RILD Building, Barrack Road, Exeter, EX2 5DW, UK.
Alberto PuglieseDiabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
University of Exeter · GBBaylor College of Medicine · USBreakthrough T1D · USKarolinska Institutet · SELund University · SEPirkanmaa Hospital District · FIUniversity of Florida · USUniversity of Miami · USUniversity of Oslo · NOUNSW Sydney · AU

Funding

Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9M
Medical Research Council MR/P010695/1NIAID NIH HHS P01 AI042288
6 · The paper itself

Abstract

In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1 diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes, mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given time and that enteroviruses may become replication defective, which could explain why they have been isolated from the pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only means by which the role of viruses in type 1 diabetes can be finally proven or disproven.

Indexed as

Adaptive ImmunityAntiviral AgentsAutoimmunityBiological Specimen BanksDiabetes Mellitus, Type 1Enterovirus InfectionsHumansImmunity, InnateInsulin-Secreting CellsPancreasViral VaccinesAntiviral AgentsViral VaccinesAntiviral therapyAutoimmunityBeta cellsEnterovirusPancreasPreventionType 1 diabetesVaccineVirus

Identifiers

PMID30675626
PMCPMC6450860
OpenAlexW2914264295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.